Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study

医学 安慰剂 内科学 不利影响 临床终点 人口 2019年冠状病毒病(COVID-19) 临床试验 疾病 传染病(医学专业) 替代医学 环境卫生 病理
作者
Xiaohong Fan,Xiahong Dai,Yun Ling,Lihua Wu,Lingling Tang,Chunxian Peng,Chaolin Huang,Hongyan Liu,Hongzhou Lu,Xinghua Shen,Wei Zhang,Furong Wang,Guangming Li,Ming Li,Yanming Huang,Hongying Zhang,Minghui Li,Fei Ren,Yuanyuan Li,Chenfan Liu
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (2): 129-139 被引量:25
标识
DOI:10.1016/s1473-3099(23)00577-7
摘要

BackgroundSpread of SARS-CoV-2 led to a global pandemic, and there remains unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has potent activity against SARS-CoV-2, was compared with a placebo in this phase 3 study to investigate its efficacy and safety in patients with mild-to-moderate COVID-19.MethodsThis multicentre, double-blind, phase 3, randomised controlled study enrolled adults in hospitals for infectious diseases and tertiary general hospitals in China. Eligible patients were randomly assigned in a 1:1 ratio using permuted block randomisation to receive oral VV116 (0·6 g every 12 h on day 1 and 0·3 g every 12 h on days 2–5) or oral placebo (on the same schedule as VV116) for 5 days. Randomisation stratification factors included SARS-CoV-2 vaccination status and the presence of high-risk factors for progression to severe COVID-19. Inclusion criteria were a positive SARS-CoV-2 test, an initial onset of COVID-19 symptoms 3 days or less before the first study dose, and a score of 2 or more for any target COVID-19-related symptoms in the 24 h before the first dose. Patients who had severe or critical COVID-19 or who had taken any antiviral drugs were excluded from the study. The primary endpoint was the time to clinical symptom resolution for 2 consecutive days. Efficacy analyses were performed on a modified intention-to-treat population, comprising all patients who received at least one dose of VV116 or placebo, tested positive for SARS-CoV-2 nucleic acid, and did not test positive for influenza virus before the first dose. Safety analyses were done on all participants who received at least one dose of VV116 or placebo. This study was registered with ClinicalTrials.gov, NCT05582629, and has been completed.FindingsA total of 1369 patients were randomly assigned to treatment groups and 1347 received either VV116 (n=674) or placebo (n=673). At the interim analysis, VV116 was superior to placebo in reducing the time to sustained clinical symptom resolution among 1229 patients (hazard ratio [HR] 1·21, 95% CI 1·04–1·40; p=0·0023). At the final analysis, a substantial reduction in time to sustained clinical symptom resolution was observed for VV116 compared with placebo among 1296 patients (HR 1·17, 95% CI 1·04–1·33; p=0·0009), consistent with the interim analysis. The incidence of adverse events was similar between groups (242 [35·9%] of 674 patients vs 283 [42·1%] of 673 patients).InterpretationAmong patients with mild-to-moderate COVID-19, VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns.FundingShanghai Vinnerna Biosciences, Shanghai Science and Technology Commission, and the National Key Research and Development Program of China.TranslationFor the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
asd113发布了新的文献求助10
2秒前
美满的小蘑菇完成签到 ,获得积分10
2秒前
自然白安完成签到 ,获得积分10
8秒前
量子星尘发布了新的文献求助10
11秒前
等待小鸽子完成签到 ,获得积分10
13秒前
龙虾发票完成签到,获得积分10
20秒前
小康学弟完成签到 ,获得积分10
20秒前
了0完成签到 ,获得积分10
20秒前
慕青应助科研通管家采纳,获得10
23秒前
彭于晏应助科研通管家采纳,获得30
23秒前
毛豆爸爸应助科研通管家采纳,获得20
23秒前
林利芳完成签到 ,获得积分0
24秒前
JaneChen完成签到 ,获得积分10
26秒前
健壮惋清完成签到 ,获得积分10
26秒前
27秒前
gabee完成签到 ,获得积分10
31秒前
liang19640908完成签到 ,获得积分10
34秒前
奋斗的雪曼完成签到 ,获得积分10
40秒前
粗心的飞槐完成签到 ,获得积分10
40秒前
LELE完成签到 ,获得积分10
47秒前
了0完成签到 ,获得积分10
48秒前
apocalypse完成签到 ,获得积分10
53秒前
guhao完成签到 ,获得积分10
54秒前
指导灰完成签到 ,获得积分10
54秒前
善良的火完成签到 ,获得积分10
1分钟前
优雅夕阳完成签到 ,获得积分10
1分钟前
Jasper应助光亮的自行车采纳,获得10
1分钟前
miki完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
糖宝完成签到 ,获得积分10
1分钟前
KX2024完成签到,获得积分10
1分钟前
松松发布了新的文献求助20
1分钟前
nusiew完成签到,获得积分10
1分钟前
huiluowork完成签到 ,获得积分10
1分钟前
陶醉的翠霜完成签到 ,获得积分10
1分钟前
1分钟前
冷静如松完成签到 ,获得积分10
1分钟前
1分钟前
浮云完成签到 ,获得积分10
1分钟前
屈岂愈完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022